RE Medicine Received A Few Millions of Dollars In Series Pre-A Financing

Innovative cancer treatment company RE Medicine just received a few million dollars of funding in Series Pre-A financing. This round of financing was led by Lang Sheng Investment. The funds will be used to accelerate the development of RE Medicine's compound steep pulse therapy device.

Established in September 2016, RE Medicine is engaged in the development, production and sales of medical devices. The company's production and research center are located in Shanghai. In the past three years, RE Medicine has made major breakthroughs in the field of prostate cancer, and has developed products that are better than foreign one in the field of Nano-knife technology. The company's compound steep pulse therapy equipment is expected to be available to the market in the second half year of 2020.

At the end of May 2019, RE Medicine's product to treat prostate cancer has received good reviews from patients and doctors due to its good effect.

Lang Sheng Investment is a leading life science and big data investment firm in China committed to helping exceptional entrepreneurs build the next generation of great healthcare and big data companies.